No comparative trials are available to assess the efficacy of vigabatrin compared to other anticonvulsants, including newer drugs, such as oxcarbazepin, felbamate, lamotrigine and topiramate which are approved in some EU Member States for childhood epilepsy in children over 2-4 years of age.